- Home
- YMAB
as 01-21-2025 4:00pm EST
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 482.4M | IPO Year: | 2018 |
| Target Price: | $21.10 | AVG Volume (30 days): | 417.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.01 - $20.90 | Next Earning Date: | 02-27-2025 |
| Revenue: | $84,553,000 | Revenue Growth: | -8.99% |
| Revenue Growth (this year): | 6.09% | Revenue Growth (next year): | 19.62% |
Latest Y-mAbs Therapeutics Inc. News
YMAB Breaking Stock News: Dive into YMAB Ticker-Specific Updates for Smart Investing
TipRanks
11 days ago
Y-mAbs Therapeutics Announces Strategic Business Realignment
MT Newswires
12 days ago
Y-mAbs Therapeutics Establishing Two New Business Units, Reports 2024 Preliminary Net Revenue
GlobeNewswire
12 days ago
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
GlobeNewswire
12 days ago
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
GlobeNewswire
12 days ago
Y-mAbs Provides Strategic Business Update and 2025 Priorities
TipRanks
14 days ago
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
MT Newswires
15 days ago
BofA Securities Adjusts Price Target on Y-mAbs Therapeutics to $14 From $17, Maintains Neutral Rating
GlobeNewswire
a month ago
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Compare YMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "YMAB Y-mAbs Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.